Seroba Life Sciences

Perfuze is a neurovascular medical device company based in Galway, Ireland, founded in 2018. The company focuses on developing innovative catheter technology specifically for the treatment of acute ischemic stroke. Perfuze aims to enhance clinical outcomes and reduce procedural times through its proprietary catheter-based aspiration technology, which optimizes the efficiency of clot removal. By simplifying procedures and minimizing the need for alternative treatment methods, Perfuze seeks to provide cost-effective solutions for patients suffering from ischemic stroke.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Their primary focus is creating treatments for rare retinal disorders using a recombinant adeno-associated virus vector, which delivers a functional copy of the PDE6B gene directly between photoreceptors and the retinal pigment epithelium to provide effective visual restoration.

Deciphex Limited, founded in 2017 and headquartered in Dublin, Ireland, specializes in developing digital pathology software applications that leverage artificial intelligence to enhance diagnostic workflows. The company offers two primary platforms: Diagnexia, which facilitates rapid diagnostics by connecting global subspecialty pathologists to address backlogs, and Patholytix Preclinical, designed for optimizing preclinical safety assessments in pharmaceutical research. By automating routine tasks and triaging high-volume, low-complexity samples, Deciphex enables pathologists to concentrate on more complex cases, ultimately improving productivity and patient outcomes. Through its innovative approach, Deciphex is committed to advancing healthcare delivery and therapeutic development.

ShiraTronics, Inc. is a company focused on developing and commercializing innovative therapies for the treatment of chronic migraines. Incorporated in 2018 and headquartered in Ireland, with an additional location in Minneapolis, Minnesota, ShiraTronics utilizes advanced neuromodulation technology to address the unmet clinical needs of patients suffering from debilitating migraine headaches. The company's mission is to transform the lives of those affected by this widespread and disabling disorder, which impacts millions globally, by providing effective solutions that enhance their quality of life.

Loci Orthopaedics Limited, established in 2017 and headquartered in Upper Newcastle, Ireland, specialises in the manufacture of medical instruments, notably the InDx implant. This innovative device is designed to mimic natural thumb joint motions and offers a less invasive surgical solution for patients with arthritis in their thumb base joint, addressing a significant unmet clinical need in orthopaedics.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Artica Therapeutics is a biotechnology company focused on the research and development of innovative therapies aimed at treating severe autoimmune and inflammatory disorders. The company employs label-free cellular-based screening methods, which facilitate the rapid advancement of drug candidates through the development process. This approach enables healthcare professionals to more effectively address the needs of patients suffering from these complex conditions. Additionally, Artica Therapeutics is involved in the development of medical devices and pharmaceutical processes, underscoring its commitment to advancing healthcare solutions.

Shorla Pharma Limited is an Irish specialty pharmaceutical company focused on developing and manufacturing oncology drugs for orphan and pediatric cancers. Established in 2017 and headquartered in Clonmel, Ireland, with an additional office in New York, the company aims to provide accessible and affordable life-saving treatments. Its product portfolio includes SH-111, a sterile injectable solution designed to treat T-cell leukemia in both pediatric and adult patients, as well as SH-105, another oncology drug. Shorla Pharma is dedicated to enhancing patient care and making a significant clinical impact through its innovative therapies.

Complement Therapeutics is a preclinical stage biotechnology company focused on addressing chronic diseases linked to the dysregulation of the complement system. The company has developed a precision medicine diagnostic platform that stratifies patients according to their complement-activation profiles. This innovative approach not only facilitates patient selection for future clinical trials but also serves as an efficacy biomarker, potentially enhancing medical treatment outcomes. By leveraging its platform methodology, Complement Therapeutics aims to improve the precision of treatments for patients suffering from conditions influenced by complement system dysregulation.

Deciphex Limited, founded in 2017 and headquartered in Dublin, Ireland, specializes in developing digital pathology software applications that leverage artificial intelligence to enhance diagnostic workflows. The company offers two primary platforms: Diagnexia, which facilitates rapid diagnostics by connecting global subspecialty pathologists to address backlogs, and Patholytix Preclinical, designed for optimizing preclinical safety assessments in pharmaceutical research. By automating routine tasks and triaging high-volume, low-complexity samples, Deciphex enables pathologists to concentrate on more complex cases, ultimately improving productivity and patient outcomes. Through its innovative approach, Deciphex is committed to advancing healthcare delivery and therapeutic development.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Sibylla Biotech S.R.L. is an Italian biotechnology company focused on the research and development of innovative solutions for drug design. The company specializes in producing small molecule folding interfering degraders (FIDs) that target various therapeutic areas. Sibylla Biotech employs advanced patent-based software that utilizes algorithms and drug design protocols to enhance drug discovery processes. By implementing original reaction path sampling and data reduction techniques, the software aims to streamline the development of treatments for incurable diseases. In addition to its product development, Sibylla Biotech offers consultancy services in biotechnology and drug development, supporting medical practitioners in rationalizing their research efforts. The company is headquartered in Italy.

Perfuze is a neurovascular medical device company based in Galway, Ireland, founded in 2018. The company focuses on developing innovative catheter technology specifically for the treatment of acute ischemic stroke. Perfuze aims to enhance clinical outcomes and reduce procedural times through its proprietary catheter-based aspiration technology, which optimizes the efficiency of clot removal. By simplifying procedures and minimizing the need for alternative treatment methods, Perfuze seeks to provide cost-effective solutions for patients suffering from ischemic stroke.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Their primary focus is creating treatments for rare retinal disorders using a recombinant adeno-associated virus vector, which delivers a functional copy of the PDE6B gene directly between photoreceptors and the retinal pigment epithelium to provide effective visual restoration.

Palliare is a medical technology company focused on advancing smoke insufflation and evacuation solutions tailored for various surgical applications, including robotic, laparoscopic, endoluminal, and colorectal procedures. The company offers products such as the EVA15 insufflator and a specialized smoke evacuation system, designed to enhance surgical workflows while safeguarding operating room staff from the dangers of surgical smoke and aerosolized viruses. Palliare aims to establish itself as a leader in the field of advanced insufflation technology, addressing the needs of minimally invasive surgery and providing hospitals with effective solutions for smoke management during surgical procedures.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Atlantic Therapeutics Limited is a medical technology company based in Galway, Ireland, with additional offices in London, Paris, and Salem. Established in 2013, the company specializes in the manufacture and distribution of medical devices designed for pelvic floor muscle strengthening and nerve stimulation. Its key products include Innovotherapy, a device aimed at enhancing pelvic floor muscle function, and INNOVO, a wearable device specifically targeting stress urinary incontinence by addressing its underlying causes. Atlantic Therapeutics distributes its products through a network of distributors across Ireland, the United Kingdom, France, Germany, and the Middle East. The company operates as a subsidiary of Bio-Medical Research Limited.

Shorla Pharma Limited is an Irish specialty pharmaceutical company focused on developing and manufacturing oncology drugs for orphan and pediatric cancers. Established in 2017 and headquartered in Clonmel, Ireland, with an additional office in New York, the company aims to provide accessible and affordable life-saving treatments. Its product portfolio includes SH-111, a sterile injectable solution designed to treat T-cell leukemia in both pediatric and adult patients, as well as SH-105, another oncology drug. Shorla Pharma is dedicated to enhancing patient care and making a significant clinical impact through its innovative therapies.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Hamilton, Canada, specializing in the development of next-generation radiopharmaceuticals as precision medicines for challenging cancers. The company leverages its Targeted Alpha Therapies platform and proprietary Fast-Clear linker technology to connect alpha particle-emitting isotopes with antibodies and other targeting molecules, enabling selective delivery of cytotoxic payloads to tumors. Its lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, Fusion is conducting preclinical studies to explore the combination of FPI-1434 with approved checkpoint inhibitors and DNA damage response inhibitors to enhance anti-tumor activity. The company is also advancing FPI-1966, aimed at treating head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014, Fusion Pharmaceuticals aims to innovate within the field of radiopharmaceuticals, transforming internalizing antibodies into effective cytotoxic drugs for improved cancer treatment outcomes.

PQ Bypass is a medical device company based in Milpitas, California, focused on transforming the treatment of long-segment peripheral artery disease through minimally-invasive endovascular solutions. Founded in 2009, the company develops and manufactures devices such as the DETOUR System, PQ Snare, PQ Crossing Device, and TORUS Stent Graft System to treat peripheral vascular disease via percutaneous surgical bypass. The executive team at PQ Bypass includes recognized leaders from the medical device industry with extensive experience in developing innovative solutions for venture-backed startups and major corporations like Medtronic, Abbott, Johnson & Johnson, Covidien, and Stryker.

Atlantic Therapeutics Limited is a medical technology company based in Galway, Ireland, with additional offices in London, Paris, and Salem. Established in 2013, the company specializes in the manufacture and distribution of medical devices designed for pelvic floor muscle strengthening and nerve stimulation. Its key products include Innovotherapy, a device aimed at enhancing pelvic floor muscle function, and INNOVO, a wearable device specifically targeting stress urinary incontinence by addressing its underlying causes. Atlantic Therapeutics distributes its products through a network of distributors across Ireland, the United Kingdom, France, Germany, and the Middle East. The company operates as a subsidiary of Bio-Medical Research Limited.

Endotronix Inc. is a medical technology company based in Lisle, Illinois, founded in 2007. It specializes in the development of advanced hemodynamic monitoring solutions aimed at improving the management of heart failure. The company’s flagship product is a miniaturized, wireless implantable pressure sensor that is designed to be used during interventional cardiovascular procedures. This sensor interfaces with an external measurement device and is part of a broader platform that includes a cloud-based disease management system. Through its innovative technology, Endotronix enables healthcare professionals to detect worsening heart failure earlier, facilitating proactive patient management and enhancing clinical outcomes. The company's approach connects patients, clinicians, and reimbursement teams, providing a comprehensive solution for outpatient hemodynamic management.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Hamilton, Canada, specializing in the development of next-generation radiopharmaceuticals as precision medicines for challenging cancers. The company leverages its Targeted Alpha Therapies platform and proprietary Fast-Clear linker technology to connect alpha particle-emitting isotopes with antibodies and other targeting molecules, enabling selective delivery of cytotoxic payloads to tumors. Its lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, Fusion is conducting preclinical studies to explore the combination of FPI-1434 with approved checkpoint inhibitors and DNA damage response inhibitors to enhance anti-tumor activity. The company is also advancing FPI-1966, aimed at treating head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014, Fusion Pharmaceuticals aims to innovate within the field of radiopharmaceuticals, transforming internalizing antibodies into effective cytotoxic drugs for improved cancer treatment outcomes.

MedLumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company develops integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method that offers detailed sectional information about tissue. MedLumics' radiofrequency cardiac ablation system provides real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation enhances procedural safety, reduces technical complexity, and lowers recurrence rates for patients undergoing treatment.

Atlantic Therapeutics Limited is a medical technology company based in Galway, Ireland, with additional offices in London, Paris, and Salem. Established in 2013, the company specializes in the manufacture and distribution of medical devices designed for pelvic floor muscle strengthening and nerve stimulation. Its key products include Innovotherapy, a device aimed at enhancing pelvic floor muscle function, and INNOVO, a wearable device specifically targeting stress urinary incontinence by addressing its underlying causes. Atlantic Therapeutics distributes its products through a network of distributors across Ireland, the United Kingdom, France, Germany, and the Middle East. The company operates as a subsidiary of Bio-Medical Research Limited.

Prexton Therapeutics SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2012. It specializes in the development of innovative drugs for Parkinson's disease and other brain disorders. The company focuses on targeting metabotropic glutamate receptors, specifically mGluR4 and mGluR3, utilizing a novel scientific approach that integrates molecular, behavioral, and chemical technologies. Prexton Therapeutics aims to improve the quality of life for patients by offering alternatives to traditional dopaminergic treatments through its unique mGluR4 PAM series. This approach allows for quicker initiation of treatment, potentially leading to better medical outcomes for individuals suffering from these conditions.

Veryan Medical Ltd. is a UK-based company that specializes in the design and development of innovative vascular stent technology. Established in 2003 as a spin-out from Imperial College London, the company focuses on its proprietary BioMimics 3D technology, which employs biomimicry principles to enhance stent performance. This technology features a unique three-dimensional helical geometry that replicates natural curvature, promoting improved blood flow dynamics and reducing the risk of complications such as restenosis. Veryan Medical's stents are particularly aimed at treating patients with symptomatic peripheral arterial disease in the lower limbs, facilitating quicker initiation of treatment and potentially leading to better health outcomes. The company operates a research and development facility in Galway, Ireland, and, as of December 2018, is a subsidiary of Otsuka Medical Devices Co., Ltd.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Heart Metabolics Limited is a pharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens, making it harder for blood to leave the heart and often leading to heart failure or sudden death. With over 100,000 cases in the United States alone, HCM can be particularly severe in young adults and athletes. Current cardiovascular drugs do not help all patients, highlighting a significant medical need. Heart Metabolics is addressing this by developing perhexiline, an approved drug in Australia and New Zealand for angina, as a therapeutic for all types of HCM. The company plans to conduct clinical trials in the U.S. and seek FDA approval for perhexiline as an orphan drug, which it has already designated.

Apica Cardiovascular is a pre-revenue medical device company specializing in a technology for accessing and closing the heart's apex and peripheral vascular system. This technology standardizes access and closure for large bore therapeutic devices without blood loss, enabling minimally invasive surgical or percutaneous procedures on the beating heart. It has applications in Transcatheter Heart Valves (TAVI), Abdominal Aortic Aneurysm (AAA) repair, and Left Ventricular Assist Device (LVAD) implantation. After successful animal and cadaver model testing, the technology is now advancing towards initial clinical trials.

Covagen is a biopharmaceutical company specializing in the development of bispecific therapeutics known as FynomAbs, which are created by genetically fusing human Fynomer binding proteins to antibodies. This innovative approach allows Covagen to design therapeutics with unique architectures, enhancing their efficacy in treating inflammatory diseases and cancer. The company aims to explore novel biological pathways with each product candidate, with its lead FynomAb, COVA322, currently being developed for inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis. Founded in 2007 as a spin-off from ETH Zurich, Covagen has established strategic collaborations, notably with Mitsubishi Tanabe, to advance its drug development initiatives. The company is supported by a diverse group of investors committed to its research and therapeutic programs.

Biosensia Ltd. is a Dublin-based company specializing in point-of-care in-vitro diagnostics. It has developed RapiPlex, an innovative diagnostic system designed to deliver both quantitative and qualitative laboratory test results. This system features a disposable assay cartridge and a compact tabletop instrument, allowing for the transition of complex immunoassays from centralized laboratories to doctors' offices or patients' bedsides. RapiPlex facilitates near-patient care by providing rapid and practical testing solutions across various applications, including theranostic identification and monitoring, as well as veterinary and food safety testing. The platform is compatible with multiple biological sample types, such as whole blood, plasma, serum, urine, saliva, and milk. Founded in 2000 and previously known as NanoComms Ltd., Biosensia Ltd. rebranded in 2006 and currently operates as a subsidiary of Kypha Inc.

Veryan Medical Ltd. is a UK-based company that specializes in the design and development of innovative vascular stent technology. Established in 2003 as a spin-out from Imperial College London, the company focuses on its proprietary BioMimics 3D technology, which employs biomimicry principles to enhance stent performance. This technology features a unique three-dimensional helical geometry that replicates natural curvature, promoting improved blood flow dynamics and reducing the risk of complications such as restenosis. Veryan Medical's stents are particularly aimed at treating patients with symptomatic peripheral arterial disease in the lower limbs, facilitating quicker initiation of treatment and potentially leading to better health outcomes. The company operates a research and development facility in Galway, Ireland, and, as of December 2018, is a subsidiary of Otsuka Medical Devices Co., Ltd.

NOvate Medical Technologies is a medical device development company based in New Orleans, dedicated to creating high-quality, low-cost, and sustainable medical products that address pressing global health challenges. The company's flagship product, InfaClip, is a patented disposable obstetric device designed to simultaneously cut, clamp, and shield the infant, mother, and birthing attendant from potential infections. This innovative device aims to significantly reduce maternal and neonatal mortality rates, particularly in developing countries, by enhancing the safety of childbirth and allowing healthcare professionals to manage clots effectively. Through its focus on affordability and sustainability, NOvate Medical Technologies strives to improve healthcare outcomes in underserved communities.

Provesica is a Cambridge-based biopharmaceutical company specialising in overactive bladder. The Company’s development compound, XEN-D0501, is highly potent antagonist of the vanilloid receptor, TRPV1, and is about to start Phase 2 clinical development. In addition to XEN-D0501, Provesica owns a portfolio of intellectual property covering diverse TRPV1 antagonists suitable for development in overactive bladder or other indications where TRPV1 has been validated as an intervention target. Provesica was established in 2010 following the demerger of the overactive bladder and TRPV1 interests of Xention Ltd, an ion channel specialist drug discovery and development company. Provesica has so far raised £4 million in finance to progress its lead programme through Phase 2 development.

Covagen is a biopharmaceutical company specializing in the development of bispecific therapeutics known as FynomAbs, which are created by genetically fusing human Fynomer binding proteins to antibodies. This innovative approach allows Covagen to design therapeutics with unique architectures, enhancing their efficacy in treating inflammatory diseases and cancer. The company aims to explore novel biological pathways with each product candidate, with its lead FynomAb, COVA322, currently being developed for inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis. Founded in 2007 as a spin-off from ETH Zurich, Covagen has established strategic collaborations, notably with Mitsubishi Tanabe, to advance its drug development initiatives. The company is supported by a diverse group of investors committed to its research and therapeutic programs.

Veryan Medical Ltd. is a UK-based company that specializes in the design and development of innovative vascular stent technology. Established in 2003 as a spin-out from Imperial College London, the company focuses on its proprietary BioMimics 3D technology, which employs biomimicry principles to enhance stent performance. This technology features a unique three-dimensional helical geometry that replicates natural curvature, promoting improved blood flow dynamics and reducing the risk of complications such as restenosis. Veryan Medical's stents are particularly aimed at treating patients with symptomatic peripheral arterial disease in the lower limbs, facilitating quicker initiation of treatment and potentially leading to better health outcomes. The company operates a research and development facility in Galway, Ireland, and, as of December 2018, is a subsidiary of Otsuka Medical Devices Co., Ltd.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Opsona Therapeutics is a Dublin-based drug development company specializing in immunology, particularly the modulation of innate immunity pathways. Founded in 2004, the company has developed innovative therapeutic approaches aimed at treating autoimmune and inflammatory diseases, as well as cancer. By targeting the innate immune system, Opsona addresses a spectrum of significant health challenges, including transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. The company seeks to improve patient outcomes through its novel drug candidates and strategies, positioning itself as a leader in emerging immunology research and drug development in Europe.

Opsona Therapeutics is a Dublin-based drug development company specializing in immunology, particularly the modulation of innate immunity pathways. Founded in 2004, the company has developed innovative therapeutic approaches aimed at treating autoimmune and inflammatory diseases, as well as cancer. By targeting the innate immune system, Opsona addresses a spectrum of significant health challenges, including transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. The company seeks to improve patient outcomes through its novel drug candidates and strategies, positioning itself as a leader in emerging immunology research and drug development in Europe.

Biosensia Ltd. is a Dublin-based company specializing in point-of-care in-vitro diagnostics. It has developed RapiPlex, an innovative diagnostic system designed to deliver both quantitative and qualitative laboratory test results. This system features a disposable assay cartridge and a compact tabletop instrument, allowing for the transition of complex immunoassays from centralized laboratories to doctors' offices or patients' bedsides. RapiPlex facilitates near-patient care by providing rapid and practical testing solutions across various applications, including theranostic identification and monitoring, as well as veterinary and food safety testing. The platform is compatible with multiple biological sample types, such as whole blood, plasma, serum, urine, saliva, and milk. Founded in 2000 and previously known as NanoComms Ltd., Biosensia Ltd. rebranded in 2006 and currently operates as a subsidiary of Kypha Inc.

TriMed Research, Inc. engages in the research and development of therapeutic products primarily related to mammary gland protein designated as MAA.

Diabetica Ltd was established in September 2004 to commercialise discoveries at the Diabetes Research Group in the University of Ulster, under the leadership of scientific co-founders Prof Peter Flatt, Dr Neville McClenaghan and Prof Finbarr O'Harte.

Opsona Therapeutics is a Dublin-based drug development company specializing in immunology, particularly the modulation of innate immunity pathways. Founded in 2004, the company has developed innovative therapeutic approaches aimed at treating autoimmune and inflammatory diseases, as well as cancer. By targeting the innate immune system, Opsona addresses a spectrum of significant health challenges, including transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. The company seeks to improve patient outcomes through its novel drug candidates and strategies, positioning itself as a leader in emerging immunology research and drug development in Europe.

Azafaros B.V., based in Leiden, the Netherlands, specializes in the development of therapeutic agents aimed at treating rare metabolic disorders, specifically lysosomal storage disorders. The company focuses on innovative oral medications made from aza-sugar compounds, which were originally discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC, and have been exclusively licensed to Azafaros. These promising therapeutic agents are designed to address critical disease pathways by targeting the central nervous system and altering the metabolism of glycosphingolipids through a unique dual mode of action. Azafaros seeks to improve patient outcomes and enhance the quality of life for individuals affected by these severe inherited conditions.